cancer

Silexion Therapeutics Corp. (NASDAQ:SLXN) revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer. The additional preclinical data show that SIL-204 exhibits significant synergistic...

On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted a conditional marketing authorization to Amgen Inc’s (NASDAQ:AMGN) Imdylltra for extensive-stage small cell lung cancer with disease progression on or after at least two prior lines of therapy. Small cell...

Pyxis Oncology, Inc. (NASDAQ:PYXS) announced on Thursday, a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201. Pyxis Oncology’s second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201....

On Monday, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson & Johnson’s (NYSE:JNJ) Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients...

On Thursday, Aura Biosciences, Inc. (NASDAQ:AURA) revealed early data from an ongoing Phase 1 trial of bel-sar (AU-011) in patients with non-muscle-invasive bladder cancer (NMIBC). To date, the trial includes 13 patients, with the primary endpoints of evaluating the safety and feasibility...

Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER. Overall, the updated analysis reveals a 56% objective response rate (ORR) in patients treated...

Ideaya Biosciences Inc. (NASDAQ:IDYA), a precision medicine oncology company, released interim Phase 2 clinical trial data. The data centers on darovasertib in neoadjuvant (therapy before surgery) for uveal melanoma (UM) and an FDA Type C meeting on registrational trial design for regulatory...

ARK Invest’s multiomics analyst, Nemo M Despot, and the firm’s leader, Cathie Wood, have hinted at a revolutionary approach to healthcare, leveraging multiomics, artificial intelligence, and big data. What Happened: On Thursday, Despot, a multiomics analyst at ARK Invest, took...

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares closed slightly higher Wednesday after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of...

Turnstone Biologics Corp. (NASDAQ:TSBX) stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday. TIDAL-01 is a tumor-infiltrating lymphocyte therapy. In cancer therapy,...

Editor’s Note: This story has been updated with more details. The tech industry is mourning the loss of Susan Wojcicki, the former CEO of YouTube, who has succumbed to cancer. Her death has sparked a wave of tributes, including a heartfelt message from Sundar Pichai, the CEO of Google-...

In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a Delaware court filing last week, is intended to significantly reduce Pfizer’s potential liability,...

ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with ...

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the...

Following the unexpected cancer diagnosis of Kate Middleton (aka Catherine, Princess of Wales), several prominent figures have come forward to express their support. What Happened: First Lady Jill Biden, Ivanka Trump, former first daughter, First Lady of Florida Casey DeSantis and Jeff Bezos...